Galcanezumab

(Emgality)

Galcanezumab

Drug updated on 11/16/2023

Dosage FormInjection (subcutaneous; 100 mg/mL, 120 mg/mL)
Drug ClassCalcitonin-gene related peptide antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated in adults for the preventive treatment of migraine.
  • Indicated in adults for the treatment of episodic cluster headache.

Product Monograph / Prescribing Information

Document TitleYearSource
Emgality (Galcanezumab-gnlm) Prescribing Information 2021Eli Lilly and Company, Indianapolis, IN

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.2023Cephalagia
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.2023Cephalagia
Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review. 2023Cureus
Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies. 2023Clinical Drug Investigation
Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis. 2023The Clinical Journal of Pain
"Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. 2023Cephalalgia
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis.2022The Journal of Headache and Pain
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.2022European Journal of Medical Research
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.2022The Journal of Headache and Pain
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta‑analysis. 2021Journal of Neurology
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. 2021Frontiers in Pharmacology
Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. 2021Cephalalgia
Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials. 2021Journal of Neurology
Systematic literature review and Bayesian network meta-analysis of episodic cluster headache drugs. 2021European Review for Medical and Pharmacological Science
Calcitonin gene-related peptide monoclonal antibodies versus botulinum neurotoxin A in the preventive treatment of chronic migraine: an adjusted indirect treatment comparison meta-analysis. 2021Frontiers in Pharmacology
Combined clinical and Pharmacoeconomic report: galcanezumab (Emgality).2021CADTH
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis.2021Clinical Neurology and Neurosurgery
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials. 2020Therapeutic Advances in Neurological Disorders
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. 2020BMC Neurology
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta‑analysis. 2020Journal of Neurology
Galcanezumab for preventing migraine.2020NICE
Galcanezumab for the management of migraine: a systematic review and meta-analysis of randomized placebo-controlled trials.2020Cureus
Assessment report: Emgality. 2020EMA
CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. 2019Cephalalgia
Australian public assessment report for galcanezumab. 2019Australian Government: Department of Health
Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value.2018ICER

Clinical Practice Guidelines